Transactions – Page 3

Lumora, Inc. Sale of Heat Elution Sample Prep Technology to Roche

Lumora is a UK-based leading developer of next-generation solutions in Molecular Diagnostics products and solutions. Lumora developed a highly differentiated proprietary methodology that will enable simple and automated nucleic acid isolation in minutes instead of hours called Heat Elution. The technology is environmentally friendly and can be applied to process a wide variety of sample types including whole blood, fecal matter, sputum, FFPE tissue and buccal swabs. Convergence had been engaged by Lumora’s Board of Directors to help the Company assess strategic alternatives for the Company. …

Sale of CECity.com, Inc. to Premier, Inc.

CECity.com, Inc., headquartered in Pittsburgh, PA, is a leading provider of cloud-based healthcare solutions, specializing in performance improvement, pay-for-value reporting and continuous professional education. CECity is a leading CMS qualified PQRS registry and powers approximately 20 percent of the nation’s Qualified Clinical Data Registries (QCDRs), which are aligned with PQRS, meaningful use and emerging payment models. CECity is the exclusive performance assessment organization for the Bridges to Excellence program. Our affiliate, Seven Hills Healthcare Advisors, advised CECity in …

PBM Capital Group Acquisition of BREAS Medical AB from GE Healthcare

PBM Capital Group, LLC. is a private investment firm primarily focused on healthcare investments. Led by Paul Manning, a successful entrepreneur, we invest across all stages of corporate development– including venture capital, leveraged buyouts, growth capital, distressed/turnaround and public equity value investing– and create value by applying extensive industry knowledge and contacts, providing superior operational expertise and bringing entrepreneurial spirit to attractive investment opportunities. Breas Medical AB was founded in Gothenburg, Sweden, in 1991, and was acquired by GE …

Sale of Immco Diagnostics to Trinity Biotech

Immco, headquartered in Buffalo, New York, and employing 90 people, is a diagnostic company specializing in the development, manufacture and sale of autoimmune test kits on a worldwide basis. Immco’s product line is complemented by specialized reference laboratory services in diagnostic immunology, pathology and immunogenetics, marketed to US-based reference laboratories and hospitals. Convergence had been engaged by Immco and its financial sponsor Summit Partners, to pursue a sale of the Company. Convergence worked actively with Immco CEO Bill Maggio to craft a strategic marketing plan …